McLornan, Donal P. http://orcid.org/0000-0003-1224-091X
Czerw, Tomasz http://orcid.org/0000-0003-3108-4035
Damaj, Gandhi http://orcid.org/0000-0002-4689-3882
Ethell, Mark
Gurnari, Carmelo
Hernández-Boluda, Juan Carlos http://orcid.org/0000-0002-4289-3113
Polverelli, Nicola http://orcid.org/0000-0001-6297-9697
Schwaab, Juliana
Sockel, Katja
Raffaella, Greco http://orcid.org/0000-0002-6117-5328
Onida, Francesco
Sánchez-Ortega, Isabel
Battipaglia, Giorgia http://orcid.org/0000-0002-0695-3879
Elena, Chiara
Gotlib, Jason http://orcid.org/0000-0001-8253-6156
Reiter, Andreas
Rossignol, Julien
Ustun, Celalettin http://orcid.org/0000-0001-6896-6213
Valent, Peter http://orcid.org/0000-0003-0456-5095
Yakoub-Agha, Ibrahim
Radia, Deepti H.
Article History
Received: 24 December 2023
Revised: 4 February 2024
Accepted: 12 February 2024
First Online: 12 March 2024
Competing interests
: There was no external funding associated with this consensus-based expert opinion paper. For each individual author, declarations of interest are as below: Donal P McLornan: Advisory boards and research funding from Novartis. Educational events on behalf of Novartis. Tomasz Czerw: No relevant disclosures. Gandhi Damaj: Travel expenses from Novartis and speakers bureau/ advisory boards on behalf of Blueprint Medicines Corporation. Mark Ethell: No relevant disclosures. Carmelo Gurnari: No relevant disclosures. Juan Carlos Hernández-Boluda: No relevant disclosures. Nicola Polverelli: No relevant disclosures. Juliana Schwaab: No relevant disclosures. Katja Sockel: Advisory boards and received lecture fees from Novartis, BMS/Celgene and Blueprint Medicines Corporation. Raffaella Greco: Discloses speaking honoraria from Biotest, Pfizer, Medac, Neovii and Magenta. Francesco Onida: No relevant disclosures. Isabel Sánchez-Ortega: No relevant disclosures. Giorgia Battipaglia: No relevant disclosures. Chiara Elena: Advisory Boards for Cogent Biosciences, Blueprint Medicines Corporation, Istituto Gentili. Jason Gotlib: Incyte: Consultancy, Honoraria, Research Funding; Deciphera: Consultancy, Honoraria, Research Funding; PharmaEssentia: Consultancy, Honoraria, Research Funding; Blueprint Medicines Corporation: Consultancy, Honoraria, Research Funding; Kartos: Honoraria, Advisory committees, Research Funding; BMS: Research Funding; Abbvie: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Novartis: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Cogent Biosciences: Consultancy, Research Funding; Allakos: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Research Funding. Andreas Reiter: AbbVie: Consultancy, Honoraria, Research Funding; Blueprint Medicines Corporation: Consultancy, Honoraria, Research Funding; AOP Orphan Pharmaceuticals: Consultancy, Honoraria, Research Funding, Incyte Corporation: Consultancy, Honoraria, Research Funding; BMS: Consultancy, Honoraria, Research Funding; GSK: Consultancy, Honoraria, Research Funding; Novartis: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding. Julien Rossignol: served on an advisory board for Blueprint Medicines Corporation; and has received research grants from Blueprint Medicines Corporation, BMS, and Novartis. Celalettin Ustun: Speaker Bureau honoraria: Takeda and Blueprint Medicines Corporation. Peter Valent: Project-Related: none. Project-Independent but Related to Mastocytosis in General: Ad-Board Honoraria: Novartis, Blueprint Medicines Corporation, Cogent. Ibrahim Yakoub-Agha: No relevant disclosures. Deepti H Radia: Clinical advisory board/study steering group member (EXPLORER/PATHFINDER) for Blueprint Medicines Corporation; a study steering committee member for Cogent Biosciences; and involved in educational events and advisory boards for Novartis. Author fees for Medscape cases. Royalties for Fast Facts: Systemic Mastocytosis.